Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis
Open Access
- 10 February 2012
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 26 (7) , 1537-1546
Abstract
CCAAT/enhancer-binding protein-α (C/EBPα/CEBPA) is mutated in approximately 8% of acute myeloid leukemia (AML) in both familial and sporadic AML and, with FLT3 and NPM1, has received most attention as a predictive marker of outcome in patients with normal karyotype disease. Mutations clustering to either the N- or C-terminal (N- and C-ter) portions of the protein have different consequences on the protein function. In familial cases, the N-ter form is inherited with patients exhibiting long latency period before the onset of overt disease, typically with the acquisition of a C-ter mutation. Despite the essential insights murine models provide the functional consequences of wild-type C/EBPα in human hematopoiesis and how different mutations are involved in AML development have received less attention. Our data underline the critical role of C/EBPα in human hematopoiesis and demonstrate that C/EBPα mutations (alone or in combination) are insufficient to convert normal human hematopoietic stem/progenitor cells into leukemic-initiating cells, although individually each altered normal hematopoiesis. It provides the first insight into the effects of N- and C-ter mutations acting alone and to the combined effects of N/C double mutants. Our results mimicked closely what happens in CEBPA mutated patients.Keywords
This publication has 67 references indexed in Scilit:
- Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’British Journal of Cancer, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcomeBlood, 2009
- Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosisBritish Journal of Cancer, 2009
- Dysregulation of the C/EBPα Differentiation Pathway in Human CancerJournal of Clinical Oncology, 2009
- Antiangiogenic drugs in ovarian cancerBritish Journal of Cancer, 2008
- C/EBPα or C/EBPα oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-κB p50 bound to the bcl-2 and FLIP gene promotersLeukemia, 2008
- Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 LeukemiaCancer Cell, 2008
- Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1Blood, 2007
- C/EBPα induces PU.1 and interacts with AP-1 and NF-κB to regulate myeloid developmentBlood Cells, Molecules, and Diseases, 2007